

**Abbott Laboratories A/S
Emdrupvej 28C
2100 Copenhagen**

Business Registration No. 31 52 86 15

Annual report 2019

The Annual General Meeting adopted the annual report on 08.06.2020

Chairman of the General Meeting

Name: Fredrik Björnulfson

Contents

	<u>Page</u>
Entity details	3
Statement by Management on the annual report	4
Independent auditor's reports	5
Management commentary	8
Accounting policies	11
Income statement for 2019	16
Balance sheet at 31.12.2019	17
Statement of changes in equity for 2019	20
Notes	21

Please note that Danish decimal and digit grouping symbols have been used in the financial statements.

Entity details

Entity

Abbott Laboratories A/S
Emdrupvej 28C
DK-2100 Copenhagen Ø

Central Business Registration No: 31 52 86 15
Registered in: Copenhagen
Financial year: 01.01.2019 - 31.12.2019
Established: 04.02.1971

Board of Directors

Benjamin Edward Oosterbaan, Chairman
Fredrik Björnulfson
Ole Martin Christiansen

Executive Board

Ole Martin Christiansen, Chief Executive Officer

Auditors

Ernst & Young Godkendt Revisionspartnerselskab
Osvald Helmuths Vej 4
DK-2000 Frederiksberg

Bank

Handelsbanken, Lyngby

Statement by Management on the annual report

The Board of Directors and the Executive Board have today considered and approved the annual report of Abbott Laboratories A/S for the financial year 01.01.2019 - 31.12.2019.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

It is our opinion that the financial statements give a true and fair view of the Company's financial position at 31.12.2019 and of the results of the Company's operations for the financial year 01.01.2019 - 31.12.2019.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 08.06.2020

Executive Board

Ole Martin Christiansen
Chief Executive Officer

Board of Directors

Benjamin Edward Oosterbaan
Chairman

Fredrik Björnulfson

Ole Martin Christiansen

Independent auditor's reports

To the owners of Abbott Laboratories A/S

Opinion

We have audited the financial statements of Abbott Laboratories A/S for the financial year 1 January – 31 December 2019, which comprise income statement, balance sheet, statement of changes in equity, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2019 and of the results of the Company's operations for the financial year 1 January – 31 December 2019 in accordance with the Danish Financial Statements Act.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Independent auditor's reports

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management

- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Independent auditor's reports

Copenhagen, 08.06.2020

Ernst & Young

Godkendt Revisionspartnerselskab

CVR-nr. 30 70 02 28

Birgit Morville Schrøder

State Authorised Public Accountant

mne21337

Management commentary

	2019	2018	2017	2016	2015
	<u>DKK'000</u>	<u>DKK'000</u>	<u>DKK'000</u>	<u>DKK'000</u>	<u>DKK'000</u>
Financial highlights					
Key figures					
Revenue	162.924	128.992	147.370	133.978	140.659
Gross profit/loss	39.777	22.502	34.397	38.816	43.945
Operating profit/loss	7.834	2.983	7.823	4.747	13.788
Net financials	(32)	(2)	263	111	301
Profit/loss for the year	6.040	(2.128)	5.706	3.314	10.467
Total assets	178.470	187.175	82.679	77.382	74.454
Investments in property, and equipment	11.492	913	439	2.159	2.479
Equity	106.890	150.850	58.869	53.163	49.849
Ratios					
Gross margin (%)	24,4	17,4	23,3	28,8	31,2
Net margin (%)	3,7	-1,6	3,9	2,5	7,4
Return on equity (%)	4,7	-2,0	10,2	6,4	23,4
Solvency ratio (%)	59,9	80,6	71,0	68,7	67,0

As of 2018 the AV/SH division was transferred to Abbott Medical Danmark A/S and as a consequence of this, 2018 is not comparable with prior year's figures.

Management commentary

Primary activities

The Company's activities consist of marketing, sale and distribution of, hospital supplies, electronic medical equipment and diagnostics equipment to the hospital and health sector in Denmark, the Faroe Islands and Iceland.

Development in activities and finances

Revenue for the year amounts to 162.924 thousand compared to 128.992 from last year. Profit after tax amounts to DKK 6.040 thousand versus DKK (2.128) thousand last year. Increased sales and profit are mainly due to increased sales of FreeStyle Libre, but all divisions have encountered increased sales.

Management consider the result for the financial year satisfactory though the expected revenue and profit was not in line with our outlook from last year.

Uncertainty relating to recognition and measurement

Management evaluates that no particular uncertainties are related to recognition and measurement in connection with the presentation of the annual report.

Outlook

The company expects increasing revenue compared to 2019. For 2020 it is expected that the revenue will be from DKK 200 – 210 mio and the results will be from DKK 6 - 8 mio.

On March 11, 2020 the World Health Organization (WHO) declared a global pandemic related to coronavirus (COVID-19). During the first quarter of 2020, the coronavirus (COVID-19) pandemic affected Abbott's diversified health care businesses in various ways. Some businesses faced challenges, others have been relatively stable, and still others are performing at the levels required to successfully meet new demands.

Abbott is continually implementing business continuity plans in the face of the global crisis. Due to the critical nature of its products and services, Abbott is generally exempt from governmental orders in Denmark and other countries requiring businesses to cease operations. To protect its employees, the majority of its office-based work is being conducted remotely and the company has implemented strict travel restrictions. Abbott has taken aggressive steps to limit exposure and enhance the safety of its facilities for employees working to continue to supply healthcare products to hospital and other customers.

Due to uncertainties regarding the duration and impact of the current COVID-19 pandemic, Abbott is unable to predict the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations.

Management commentary

Abbott has mobilized its teams across multiple fronts to develop and launch three new diagnostic tests for COVID-19. In March, Abbott launched a molecular test to detect COVID-19 on its ID NOW™ rapid point-of-care platform in the U.S. pursuant to an Emergency Use Authorization (EUA). Abbott also launched a molecular test on its m2000™ RealTime lab-based platform to detect COVID-19 pursuant to an EUA in the U.S. and CE Mark. In April,

Abbott launched a serology blood test on its ARCHITECT® i1000SR and i2000SR laboratory instruments for the detection of an antibody to determine if someone was previously infected. The serology test was granted an EUA in the U.S. on April 26, 2020 and CE Mark on April 24, 2020.

Particular risks

Operating risks

The company is not exposed to any special risks besides from what is normal to the business.

Currency risks

Purchase of goods and services are mainly executed in DKK. To a minor extent, the company is invoiced in EUR, NOK, SEK and USD. Abbott Laboratories A/S do not hedge any of these amounts.

Accounting policies

Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enter-prises (medium).

The accounting policies have been applied consistently with previous years.

Consolidated financial statements

Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements are prepared. The financial statements for Abbott Laboratories A/S and its group entities are part of the consolidated financial statements for Abbott Laboratories (www.abbott.com).

Foreign currency translation

On initial recognition, foreign currency transac tions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the one in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses. Property, plant and equipment, intangible assets, inventories and other non-monetary assets that have been purchased in foreign currencies are translated using historical rates.

Operating leases

Lease payments on operating leases are recognised on a straight-line basis in the income statement over the term of the lease.

Income statement

Revenue

The Company has chosen IAS 11/IAS 18 as interpretation for revenue recognition.

Revenue from goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.

Service agreements are accrued over the term of the agreements.

Other operating income/expenses

Other operating income/expenses comprises income of a secondary nature as viewed in relation to the Entity's primary activities.

Other operating income/expenses comprise of income from divestment of divisions.

Costs of goods for resale and consumables

Costs of goods for resale and consumables comprise the consumption of goods for resale and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary write-downs of the relevant inventories.

Accounting policies

Other external expenses

Other external expenses include expenses relating to the Entity's ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes write-downs of receivables recognised in current assets.

Other external expenses also include research costs and costs of development projects that do not meet the criteria for recognition in the balance sheet.

Staff costs

Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc. for entity staff.

Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment comprise amortisation, depreciation and impairment losses for the financial year, calculated on the basis of the residual values and useful lives of the individual assets and impairment testing as well as gains and losses from the sale of intangible assets as well as property, plant and equipment.

Other financial income

Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme, etc.

Other financial expenses

Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies as well as tax surcharge under the Danish Tax Prepayment Scheme, etc.

Income taxes

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

The Company is jointly taxed with all Danish sister subsidiaries. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

Accounting policies

Balance sheet

Property, plant and equipment

Plant and machinery, other fixtures and fittings, tools and equipment as well as leasehold improvements are measured at cost less accumulated depreciation and impairment losses.

Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be put into operation.

The basis of depreciation is cost less estimated residual value after the end of useful life. Straight-line depreciation is made based on the following estimated useful lives of the assets:

Plant and machinery	3-10 years
Other fixtures and fittings, tools and equipment	3-10 years
Leasehold improvements	3-10 years

For leasehold improvements, assets subject to finance leases and for assets lent to customers recognised as operational lease contracts, the depreciation period cannot exceed the contract period.

Property, plant and equipment are written down to the lower of recoverable amount and carrying amount.

Investment in subsidiaries

Investments in subsidiaries are measured at cost. Where cost exceeds the recoverable amount, write-down is made to this lower value.

Dividends received are recognized in the income statement in the financial year in which they are declared. If proposed dividends exceed accumulated earnings after the acquisition date, dividends are however recognised as a reduction of the cost of the investment.

The carrying amount of investments in subsidiaries is subject to an annual test for indications of impairment. Write-down is made to the recoverable amount if this is lower than the carrying amount. Impairment losses are recognized in the income statement.

Deferred tax

Deferred tax is recognised on all temporary differences between the carrying amount and tax-based value of assets and liabilities, for which the tax-based value of assets is calculated based on the planned use of each asset.

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.

Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost of goods for resale and consumables consists of purchase price plus delivery costs.

The net realisable value of inventories is calculated as the estimated selling price less costs incurred to execute sale.

Income tax payable or receivable

Current tax payable or receivable is recognised in the balance sheet, stated as tax calculated on this year's taxable income, adjusted for prepaid tax.

Receivables

The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.

Receivables are measured at amortised cost, usually equalling nominal value less write-downs for bad and doubtful debts.

Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

Cash

Cash comprises cash in hand and bank deposits.

Balances in the group's cash pool scheme are not, due to the nature of the scheme, considered cash, but are recognised under 'Receivables from group entities'.

Other provisions

Other provisions comprise anticipated costs of non-recourse guarantee commitments and returns.

Other provisions are recognised and measured as the best estimate of the expenses required to settle the liabilities at the balance sheet date.

Warranty provisions comprise commitments to remedy defects and deficiencies within the guarantee period.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

Prepayments received from customers

Prepayments received from customers comprise amounts received from customers prior to delivery of the goods agreed or completion of the service agreed.

Omission to present a Cash flow statement

With reference to the section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flow is part of the consolidated cash flow statement for the parent company, Abbott Laboratories, Abbott Park, Illinois, USA.

Consolidated group financial statements including consolidated group cash flow statement may be retrieved from the following webpage: <http://www.abbott.com/investors.html>.

Accounting policies

Financial highlights

Financial highlights are defined and calculated in accordance with "Recommendations & Ratios 2015" issued by the Danish Society of Financial Analysts.

Ratios	Calculation formula
Gross margin (%)	$\frac{\text{Gross profit} \times 100}{\text{Revenue}}$
Net margin (%)	$\frac{\text{Profit/loss for the year} \times 100}{\text{Revenue}}$
Return on equity (%)	$\frac{\text{Profit/loss for the year} \times 100}{\text{Average equity}}$
Solvency ratio (%)	$\frac{\text{Equity} \times 100}{\text{Total assets}}$

Ratios reflect

Gross margin

The Entity's operating gearing.

Net margin

The Entity's operating profitability.

Return on equity

The Entity's return on capital invested in the Entity by the owners.

Solvency ratio

The financial strength of the Entity.

Income statement for 2019

	Notes	2019 DKK	2018 DKK
	_____	_____	_____
Revenue		162.924.491	128.992.247
Costs of goods of sale and consumables		(90.371.196)	(80.174.829)
Other external expenses		(32.776.371)	(26.315.488)
Gross profit/loss		39.776.924	22.501.930
Staff costs	1	(30.840.191)	(24.654.357)
Amortisation, depreciation and impairment losses	2	(1.102.321)	(830.642)
Operating profit/loss		7.834.412	(2.983.069)
Other financial income	3	141.377	95.161
Other financial expenses	4	(173.783)	(96.947)
Profit/loss from ordinary activities before tax		7.802.006	(2.984.855)
Tax on profit/loss from ordinary activities	5	(1.761.604)	856.726
Profit/loss for the year		6.040.402	(2.128.129)

Balance sheet at 31.12.2019

	<u>Notes</u>	<u>2019</u> <u>DKK</u>	<u>2018</u> <u>DKK</u>
Plant and machinery		12.612.436	2.318.117
Other fixtures and fittings, tools and equipment		83.999	52.771
Leasehold improvements		52.000	58.000
Property, plant and equipment	6	12.748.435	2.428.888
Investments			
Investment in subsidiary	7	97.197.666	97.197.666
Investments		97.197.666	97.197.666
Deferred tax		0 ¹	319.358
Fixed asset investments		0	319.358
Non-current assets		109.946.101	99.945.912

Balance sheet at. 31.12.2019

	Notes	2019 DKK	2018 DKK
Goods for resale		16.044.133	1.003.575
Inventories		16.044.133	1.003.575
Trade receivables		21.603.698	17.533.829
Receivables from group enterprises	8	13.628.212	53.600.759
Other Receivables		1.660.864	647.928
Income tax receivable		3.069.703	4.822.100
Prepayments		1.222.785	158.321
Receivables		41.185.262	76.762.937
Cash		11.294.919	9.462.628
Current assets		68.524.314	87.229.140
Assets		178.470.415	187.175.052

Balance sheet at 31.12.2019

	Notes	<u>2019</u> <u>DKK</u>	<u>2018</u> <u>DKK</u>
Contributed capital		4.026.000	4.026.000
Retained earnings		102.864.066	96.823.664
Proposed dividend		0	50.000.000
Equity		<u>106.890.066</u>	<u>150.849.664</u>
Other provisions	9	606.017	624.038
Provisions		<u>606.017</u>	<u>624.038</u>
Prepayments received from customers		5.409.673	345.178
Trade Payable		10.504.744	3.928.219
Payables to group enterprises	8	42.605.135	21.014.781
Other payables		12.237.590	10.413.172
Deferred tax	10	217.190	0
Current liabilities other than provisions		<u>70.974.332</u>	<u>35.701.350</u>
Liabilities other than provisions		<u>70.974.332</u>	<u>35.701.350</u>
Equity and liabilities		<u>178.470.415</u>	<u>187.175.052</u>
Related parties with control	8		
Appropriation of profit/loss	11		
Unrecognised rental and lease commitments	12		
Contingent liabilities	13		
Ownership	14		
Consolidation	15		
Events after the balance sheet date	16		

Statement of changes in equity for 2019

DKK	Contributed capital	Retained earnings	Dividend proposed for the year	Total
Equity at 1 January 2018	4.026.000	54.843.046	0	58.869.046
Dividend distribution	0	0	0	0
Increase of capital		94.108.747	0	94.108.747
Transfer, see " notes 11 Appropriation of profit/loss	0	(52.128.129)	50.000.000	(2.128.129)
Equity at 1 January 2019	4.026.000	96.823.664	50.000.000	150.849.664
Dividend distribution	0	0	(50.000.000)	(50.000.000)
Transfer, see " notes 11 Appropriation of profit/loss	0	6.040.402	0	6.040.402
Equity at 31 December 2019	4.026.000	102.864.066	0	106.890.066

	2019 DKK	2018 DKK	2017 DKK	2016 DKK	2015 DKK
Changes in contributed - capital					
Contributed capital beginning of year	4.026.000	4.026.000	4.026.000	4.026.000	4.026.000
Contributed capital end of year	4.026.000	4.026.000	4.026.000	4.026.000	4.026.000

	Number	Par value DKK	Nominal value DKK
Contributed capital			
Ordinary shares	4.026	1.000	4.026.000

Notes

	2019	2018
	DKK	DKK
1. Staff costs		
Wages and salaries	28.108.091	22.509.419
Pension costs	2.433.030	1.923.810
Other social security costs	299.070	221.128
	30.840.191	24.654.357
	2019	2018
Average number of full-time employees	36	29

Remuneration has not been paid to the Board of Directors in the financial year. Management remuneration is not disclosed in accordance with the exemption clause in section 98b of the Danish Financial Statements Act.

	2019	2018
	DKK	DKK
2. Amortisation, depreciation and impairment losses		
Depreciation on property, plant and equipment	1.102.321	830.642
	1.102.321	830.642

Notes

3. Other financial income	2019	2018
	DKK	DKK
Other interest income	250	1.405
Currency translation adjustments	141.127	93.756
	141.377	95.161
4. Other financial expenses	2019	2018
	DKK	DKK
Other interest expenses	57.464	38.817
Currency translation adjustments	116.319	58.130
	173.783	96.947
5. Tax on profit/loss from ordinary activities	2019	2018
	DKK	DKK
Current tax	1.196.297	(557.273)
Change in deferred tax	536.548	(435.160)
Adjustment relating to previous years	28.759	135.708
	1.761.604	(856.725)

Notes

6. Property, plant and equipment	Plant and machinery	Other fixtures and fittings, tools and equipment	Leasehold improve- ments
	<u>DKK</u>	<u>DKK</u>	<u>DKK</u>
Cost at 1 January 2019	5.658.344	726.711	268.713
Additions	11.399.165	93.145	0
Disposals	(1.000.598)	(559.285)	(208.713)
Cost at 31 December 2019	<u>16.056.911</u>	<u>260.571</u>	<u>60.000</u>
Depreciation and impairment losses at 1 January 2019	(3.340.227)	(673.940)	(210.713)
Depreciation for the year	(1.034.406)	(61.917)	(6.000)
Reversal regarding disposals	930.158	559.285	208.713
Depreciation and impairment losses at 31 December 2019	<u>(3.444.475)</u>	<u>(176.572)</u>	<u>(8.000)</u>
Carrying amount at 31 December 2019	<u>12.612.436</u>	<u>83.999</u>	<u>52.000</u>

Plant and machinery mainly consist of equipment lent to customers recognized as operational lease contracts.

Notes

7. Investments

	Investment in subsidiaries <u>DKK</u>
Cost at 1 January 2019	97.197.666
Additions	0
Disposals	0
Cost at 31 December 2019	<u>97.197.666</u>
Revaluations at 1 January 2019	0
Revaluation during the year	0
Revaluations at 31 December 2019	<u>0</u>
Carrying amount at 31 December 2019	<u>97.197.666</u>

Name and place	Ownership	Result	Equity
Subsidiary			
Abbott Medical Danmark A/S, Glostrup	100%	5.674.173	110.595.662

Notes

8. Related parties

Related parties with a controlling interest

The following related parties have a controlling interest in Abbott Laboratories A/S:

Name	Registered office	Basis of influence
Abbott Laboratories	Abbott Park, Illinois, USA	Ultimate Parent
St. Jude Medical International Holding	Luxembourg	Parent

Transactions with related parties

Related party	Country	Revenue	2019 DKK	2018 DKK
Abbott GmbH & Co. KG	Germany	Expense recharge	2.394.059	2.605.315
		Sale of goods	153.927	130.306
Abbott Laboratories Limited	UK	Sale of services	0	614.493
Abbott Norge AS	Norway	Regional allocation	3.123.670	2.974.731
Abbott Oy	Finland	Regional allocation	1.917.833	1.935.529
Abbott Scandinavia AB	Sweden	Regional allocation	2.222.560	3.239.362
Abbott Vascular International BVBA	Belgium	Expense recharge	0	27.934
Abbott International Ltd. (AIL)	USA	Expense recharge	0	134.000
Abbott Medical Danmark A/S	Denmark	Expense recharge	4.071.164	0
Alere A/S	Denmark	Sale of goods	16.373	0
		Expense recharge	573.411	0
Total			14.472.996	11.661.670

Notes

Related party	Country	Cost	2019 DKK	2018 DKK
Abbott Diagnostics GmbH	Germany	Product purchase	110.349.497	77.526.038
Abbott GmbH & Co. KG	Germany	Purchase of services	1.695.485	3.160.971
		Product purchase	0	987.183
		Expense recharge	4.499.974	0
Abbott International Ltd. (AIL)	USA	Expense recharge	357.684	0
		Product purchase	0	27.154
Abbott Laboratories LLC	USA	Expense recharge	0	(144.601)
Abbott Laboratories Limited	UK	Product purchase	(104.790)	1.308.214
		Purchase of services	2.157.080	2.450.114
		Regional allocation	2.322.019	0
Abbott B.V.	Netherlands	Purchase of services	73.160	0
Abbott Norge AS	Norway	Expense recharge	478.524	128.375
		Regional allocation	7.116.447	5.075.032
Abbott Oy	Finland	Regional allocation	407.326	284.471
Abbott Scandinavia AB	Sweden	Regional allocation	2.032.764	3.320.878
		Expense recharge	78.741	62.979
Abbott Vascular Netherlands B.V.	Netherlands	Product purchase	0	25.447.642
Abbott Vascular International BVBA	Belgium	Expense recharge	0	429.548
Abbott S.r.l.	Italy	Expense recharge	0	108.956
Omnilab S.r.l.	Italy	Product purchase	0	8.196
Abbott Ireland Limited	Ireland	Regional allocation	1.295.690	1.845.455
Alere A/S	Denmark	Product purchase	395.778	1.062.587
Grand Total			133.155.379	123.089.192

As of 1/1-2018 Abbott Laboratories A/S transferred the activities of its Vascular and Structural Heart business to Abbott Medical Danmark A/S at book value.

During the year 2018 Abbott Laboratories A/S acquired Abbott Medical Danmark A/S at book value through a capital increase.

Receivables from affiliated companies

Related party	Country	2019 DKK	2018 DKK
Abbott Laboratories Finance B.V.	Netherlands	0	53.183.270
Abbott GmbH & Co. KG	Germany	184.441	282.999
Abbott International Ltd. (AIL)	USA	13.443.771	134.400
Other sister companies		0	90
Grand Total		13.628.212	53.600.759

Notes

Payables to affiliated companies

Related party	Country	2019 DKK	2018 DKK
Abbott Laboratories Finance B.V.	Netherlands	24.207.567	0
Abbott Diagnostics GmbH	Germany	13.330.541	6.301.862
Abbott GmbH & Co. KG	Germany	1.223.813	1.124.149
Abbott Ireland Limited	Ireland	1.295.690	805.383
Abbott Laboratories International LLC	USA	(3.335)	(32.523)
Abbott Laboratories Limited	UK	2.322.019	129.255
Abbott Medical Danmark A/S	Denmark	216.272	12.697.490
Alere A/S	Denmark	0	(8.981)
Other sister companies		12.569	(1.853)
Grand Total		42.605.135	21.014.782

9. Other provision

	2019 DKK	2018 DKK
Other provisions consist of provisions for non-recourse guarantee commitments	606.017	624.038
	606.017	624.038

The Company grants a warranty of 24 months on Diagnostics products and is obliged to repair or replace products which are not satisfactory. For our Free Style Libre products, the company grants a warranty of 3 and 12 months depending on the product.

10. Deferred tax

	2019 DKK	2018 DKK
Deferred tax at 1 January	319.358	(115.802)
Adjustment of the deferred tax for the year	(536.548)	435.160
	(217.190)	319.358
The deferred tax asset relates to:		
Property, plant and equipment	(375.463)	161.552
Fixed asset investments	(200)	(20)
Inventories	24.575	18.647
Receivables from sales and services	574	1.891
Provisions	133.324	137.288
	(217.190)	319.358

Notes

11. Appropriation of profit/loss

	2019 DKK	2018 DKK
Recommended appropriation of profit/loss		
Transferred to reserves under equity	6.040.402	(2.128.129)
	<u>6.040.402</u>	<u>(2.128.129)</u>

12. Unrecognised rental and lease commitments

	2019 DKK	2018 DKK
Commitments under rental agreements or leases until expiry	3.336.956	4.221.455
<i>Due within the next 12 months</i>	1.903.509	2.587.278

13. Contingent liabilities

	2019 DKK	2018 DKK
Guarantee and warranty commitments	5.109.094	0
Contingent liabilities	<u>5.109.094</u>	<u>0</u>

The Company participates in a Danish joint taxation arrangement with Danish sister subsidiaries, with Abbott Laboratories A/S as the management company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable from the financial year 2013 for income taxes etc for the jointly taxed companies and from 01.07.2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed companies.

14. Ownership

The Company is wholly owned by St. Jude Medical International Holding, 26, Boulevard Royal, L-2449 Luxembourg.

15. Consolidation

Name and registered office of the Parent preparing consolidated financial statements:

Abbott Laboratories, Abbott Park, Illinois, USA

Notes

16. Events after the balance sheet date

See comments regarding COVID-19 in the Management commentary under Outlook. No other events materially affecting the Company's financial position have occurred subsequent to the financial year-end.